Preparation and characterization of nano-liposome-mediated FL gene in the lovo cells

Cancer Biotherapy and Radiopharmaceuticals

Volumn 27, Issue 8, 2012, Pages 490-494

  Sun, Nian Feng ^a,b   Tian, Ai Ling ^b   Hua, Yong Xin ^b   Hu, San Yuan ^a   Hu, An Bin ^c  

^a SHANDONG UNIVERSITY   (China)

^b JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

colon cancer; FL gene; gene therapy; nano liposomes

Indexed keywords

GREEN FLUORESCENT PROTEIN; LIPOSOME; NANOLIPOSOME; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL DEATH; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; ELECTRON MICROSCOPY; FLUORESCENCE MICROSCOPY; FMS LIKE TYROSINE KINASE RECEPTOR 3 LIGAND GENE; GENE; HUMAN; HUMAN CELL; MOLECULAR CLONING; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; ZETA POTENTIAL;

BASE SEQUENCE; CELL LINE, TUMOR; COLONIC NEOPLASMS; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GREEN FLUORESCENT PROTEINS; HUMANS; LIPOSOMES; MALE; MEMBRANE PROTEINS; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NANOPARTICLES; PLASMIDS; RECOMBINANT FUSION PROTEINS; TRANSFECTION;

EID: 84867491359     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1189     Document Type: Article

References (21)

1. Li S-D, Huang L. Non-viral is superior to viral gene delivery. J Control Release 2007;123:181.
2. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4:145.
3. Baoa A, Phillips WT, Goins B, et al. Potential use of drug carried-liposomes for cancer therapy via direct intratumoral injection. Int J Pharm 2006;316:162.
4. Garg A, Tisdale AW, Haidari E, Kokkoli E. Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide. Int J Pharm 2009;366:201.
5. Yonemura Y, Ku H, Lyman SD, Ogawa M. In vitro expansion of hematopoietic progenitors and maintenance of stem cells: Comparison between Flt3/Flk2 ligand and kit ligand. Blood 1997;89:1915.
6. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1532.
7. Haylock DN, Horsfall MJ, Dowse TL, et al. Increased recruitment of hematopoietic progenitor cells underlies the ex vivo expansion potential of flt3 ligand. Blood 1997;90:2260.
8. Maliszewski C. Dendritic cells in models of tumor immunity: Role of Flt3 ligand. Pathol Biol 2001;49:481.
9. Trainer DL, et al. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int J Cancer 1988;41:287.
10. Kuwai T, Nakamura T, Sasaki T, et al. Targeti1ng the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy. Clin Exp Metastasis 2008;25:477.
11. Yokoi K, Thaker PH, Yazici S, et al. Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Res 2005;65:3716e25.
12. Lindgren M, Rosenthal-Aizman K, Saar K. Overcoming metho-trexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide, Biochem Pharmacol 2006;71:416.
13. Qu G, Yao Z, Zhang C, et al. PEG conjugated N-octyl-Osulfate chitosan micelles for delivery of paclitaxel: In vitro characterization and in vivo evaluation. Eur J Pharm Sci 2009;37:98e105.
14. Mandal BB, Kundu SC. Self-assembled silk sericin/poloxamer nanoparticles as nanocarriers of hydrophobic and hydrophilic drugs for targeted delivery. Nanotechnology 2009;20:14.
15. Kundu J, Chung YI, Kim YH, et al. Silk fibroin nanoparticles for cellular uptake and control release. Int J Pharm 2010;388:242e50.
16. He M, Zhao Z, Yin L, et al. Hyaluronic acid coated poly(butyl cyanoacrylate) nanoparticles as anticancer drug carriers. Int J Pharm 2009;373:165e73.
17. Suzuki H, Kuzumaki S, Nakagawa K. Suppressive effect of modified mominant negative RAS mutant on human cancer by gene transfer with non-viral vector, Cancer Biol Ther 2006;5:1487.
18. Jönsson M, Engström M, Jönsson JI. FLT3 ligand regulates apoptosis through AKT-dependent inactivation of transcription factor FoxO3, Biochem Biophys Res Commun 2004;318:899.
19. Kim EM, Sivanandham M, Stavropoulos CI. Adjuvant effect of a Flt3 ligand (FL) gene-transduced xenogeneic cell line in a murine colon cancer model. J Surg Res 2002;108:148.
20. Maliszewski C. Dendritic cells in models of tumor immunity: Role of Flt3 ligand. Pathol Biol(Paris) 2001;49:481.
21. Ganten TM, Sykora J. Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. J Mol Med 2009;87:995.